1H MRSI and progression-free survival in patients with WHO grades II and III gliomas

Neurological Research

Volumn 32, Issue 6, 2010, Pages 593-602

  Hattingen, Elke ^a   Delic, Oliver ^a   Franz, Kea ^a   Pilatus, Ulrich ^a   Raab, Peter ^a,b   Lanfermann, Heinrich ^a,b   Gerlach, Rüdiger ^a,c  

^a GOETHE UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c HELIOS KLINIKUM ERFURT   (Germany)

Author keywords

CHOLINE; CREATINE; GLIOMAS; MR SPECTROSCOPY; PROGRESSION FREE SURVIVAL

Indexed keywords

CHOLINE; CREATINE PHOSPHATE; CREATININE; CREATINE; PROTON;

ADULT; ARTICLE; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; GLIOMA; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROIMAGING; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTON NUCLEAR MAGNETIC RESONANCE; WORLD HEALTH ORGANIZATION; AGED; BRAIN NEOPLASMS; DIAGNOSTIC USE; DISEASE COURSE; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BRAIN NEOPLASMS; CHOLINE; CREATINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PHOSPHOCREATINE; PROTONS; RETROSPECTIVE STUDIES; ROC CURVE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; YOUNG ADULT; KAPLAN-MEIER ESTIMATE;

EID: 77953852306     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164109X12478302362770     Document Type: Article

References (30)

1. Kleihues P, Cavenee WK, eds. Pathology and Genetics Tumours of the Nervous System. WHO Classification of Tumours of the Nervous System, Lyon: IARC Press, 2000
2. Kuznetsov YE, Caramanos Z, Antel SB, et al. Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. Neurosurgery 2003; 53: 565-574
3. Hattingen E, Raab P, Franz K, et al. Prognostic value of choline and creatine in WHO grade II gliomas. Neuroradiology 2008; 50: 759-767
4. Möller-Hartmann W, Herminghaus S, Krings T, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002; 44: 371-381
5. Shimizu H, Kumabe T, Shirane R, et al. Correlation between choline level measured by protonMR spectroscopy and Ki-67 labeling index in gliomas. AJNR Am J Neuroradiol 2000; 21: 659-665
6. Fayed N, Modrego PJ. The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumours. J Neurooncol 2005; 72: 261-265
7. Xu M, See SJ, Ng WH, et al. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 2005; 56: 919-926
8. McKnight TR, Lamborn KR, Love TD, et al. Correlation of magnetic resonance spectroscopic and growth characteristics within grades II and III gliomas. J Neurosurg 2007; 106: 660-666
9. Tedeschi G, Lundbom N, Raman R, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: A serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997; 87: 516-524 (Pubitemid 27430397)
10. Hermann EJ, Hattingen E, Krauss JK, et al. Stereotactic biopsy in gliomas guided by 3-tesla 1H-chemical-shift imaging of choline. Stereotact Funct Neurosurg 2008; 86: 300-307
11. Hattingen E, Raab P, Franz K, et al. Myo-inositol: A marker of reactive astrogliosis in glial tumors? NMR Biomed 2008; 21: 233-241
12. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30: 672-679
13. Hattingen E, Pilatus U, Franz K, et al. Evaluation of optimal echo time for 1H-spectroscopic imaging of brain tumors at 3 Tesla. J Magn Reson Imaging 2007; 26: 427-431
14. Wiedermann D, Schuff N, Matson GB, et al. Short echo time multislice proton magnetic resonance spectroscopic imaging in human brain: Metabolite distributions and reliability. Magn Reson Imaging 2001; 19: 1073-1080
15. Kreis R. Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed 2004; 17: 361-381
16. Kinoshita Y, Kajiwara H, Yokota A, et al. Proton magnetic resonance spectroscopy of brain tumors: An in vitro study. Neurosurgery 1994; 35: 606-613
17. Dringen R, Verleysdonk S, Hamprecht B, et al. Metabolism of glycine in primary astroglial cells: Synthesis of creatine, serine, and glutathione. J Neurochem 1998; 70: 835-840
18. Urenjak J, Williams SR, Gadian DG, et al. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993; 13: 981-989
19. Husted CA, Goodin DS, Hugg JW, et al. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 1994; 36: 157-165
20. Hanefeld FA, Brockmann K, Pouwels PJ, et al. Quantitative proton MRS of Pelizaeus-Merzbacher disease: Evidence of dysand hypomyelination. Neurology 2005; 65: 701-706
21. van der Knaap MS, Naidu S, Pouwels PJ, et al. New syndrome characterized by hypomyelination with atrophy of the basal ganglia and cerebellum. AJNR Am J Neuroradiol 2002; 23: 1466-1474
22. Galanaud D, Chinot O, Nicoli F, et al. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg 2003; 98: 269-276
23. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002; 20: 2076-2084
24. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: Data from the Glioma Outcomes Project. J Neurosurg 2003; 99: 467-473
25. Shaw EG, Scheithauer BW, O'Fallon JR. Supratentorial gliomas: A comparative study by grade and histologic type. J Neurooncol 1997; 31: 273-278
26. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64: 479-489
27. Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro-Oncol 2008; 11: 437-445
28. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008; 62: 753-764
29. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on doseresponse in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996; 36: 549-556
30. Hwang JH, Egnaczyk GF, Ballard E, et al. Proton MR spectroscopic characteristics of pediatric pilocytic astrocytomas. AJNR Am J Neuroradiol 1998; 19: 535-540